辐射卓越：十年的开创性放疗试验和协作领导在利兹癌症研究英国临床试验单位。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology Pub Date : 2025-09-10 DOI:10.1016/j.clon.2025.103937

F. Slevin , E.M. Hudson , A. Hockaday , J. Kendall , S. Noutch , J.B. Oughton , A. Smith , J.C. Webster , D. Sebag-Montefiore , S.R. Brown

{"title":"辐射卓越：十年的开创性放疗试验和协作领导在利兹癌症研究英国临床试验单位。","authors":"F. Slevin , E.M. Hudson , A. Hockaday , J. Kendall , S. Noutch , J.B. Oughton , A. Smith , J.C. Webster , D. Sebag-Montefiore , S.R. Brown","doi":"10.1016/j.clon.2025.103937","DOIUrl":null,"url":null,"abstract":"<div><div>Recently, there has been considerable development in radiotherapy technologies and novel drug-radiotherapy combinations, with the potential to develop more effective and less toxic treatments for patients. There is a need to evaluate these approaches through clinical trials, and clinical trials units (CTUs) are ideally positioned to design and deliver these studies. Over the past 10 years, the Leeds Cancer Research UK CTU has developed a flagship portfolio of radiotherapy clinical trials, which encompass novel drug-radiotherapy combinations, radiotherapy technologies and optimising radiotherapy dose. Key to the success of the portfolio has been an emphasis on multidisciplinary collaborations, career development of future leaders in clinical trials, understanding the funding landscape, engagement with discovery and translational scientists, and keeping patients at the heart of our research. Moving forward, the priorities of the CTU are to build on this strong foundation with a pipeline of impactful and scientifically rich clinical trials, which will continue to shape the radiotherapy research landscape.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"47 ","pages":"Article 103937"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Radiating Excellence: A Decade of Pioneering Radiotherapy Trials and Collaborative Leadership at Leeds Cancer Research UK Clinical Trials Unit\",\"authors\":\"F. Slevin , E.M. Hudson , A. Hockaday , J. Kendall , S. Noutch , J.B. Oughton , A. Smith , J.C. Webster , D. Sebag-Montefiore , S.R. Brown\",\"doi\":\"10.1016/j.clon.2025.103937\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Recently, there has been considerable development in radiotherapy technologies and novel drug-radiotherapy combinations, with the potential to develop more effective and less toxic treatments for patients. There is a need to evaluate these approaches through clinical trials, and clinical trials units (CTUs) are ideally positioned to design and deliver these studies. Over the past 10 years, the Leeds Cancer Research UK CTU has developed a flagship portfolio of radiotherapy clinical trials, which encompass novel drug-radiotherapy combinations, radiotherapy technologies and optimising radiotherapy dose. Key to the success of the portfolio has been an emphasis on multidisciplinary collaborations, career development of future leaders in clinical trials, understanding the funding landscape, engagement with discovery and translational scientists, and keeping patients at the heart of our research. Moving forward, the priorities of the CTU are to build on this strong foundation with a pipeline of impactful and scientifically rich clinical trials, which will continue to shape the radiotherapy research landscape.</div></div>\",\"PeriodicalId\":10403,\"journal\":{\"name\":\"Clinical oncology\",\"volume\":\"47 \",\"pages\":\"Article 103937\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S093665552500192X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093665552500192X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

近年来，放射治疗技术和新型药物-放射治疗组合有了长足的发展，有可能为患者开发出更有效、毒性更小的治疗方法。有必要通过临床试验来评估这些方法，而临床试验单位（ctu）是设计和提供这些研究的理想定位。在过去的10年里，英国利兹癌症研究中心CTU已经开发了放射治疗临床试验的旗舰产品组合，其中包括新的药物-放射治疗组合，放射治疗技术和优化放射治疗剂量。该组合成功的关键是强调多学科合作、临床试验未来领导者的职业发展、了解资助情况、与发现和转化科学家的接触，以及将患者置于我们研究的核心。展望未来，CTU的首要任务是在这个坚实的基础上建立有影响力和科学丰富的临床试验管道，这将继续塑造放疗研究的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Radiating Excellence: A Decade of Pioneering Radiotherapy Trials and Collaborative Leadership at Leeds Cancer Research UK Clinical Trials Unit

Recently, there has been considerable development in radiotherapy technologies and novel drug-radiotherapy combinations, with the potential to develop more effective and less toxic treatments for patients. There is a need to evaluate these approaches through clinical trials, and clinical trials units (CTUs) are ideally positioned to design and deliver these studies. Over the past 10 years, the Leeds Cancer Research UK CTU has developed a flagship portfolio of radiotherapy clinical trials, which encompass novel drug-radiotherapy combinations, radiotherapy technologies and optimising radiotherapy dose. Key to the success of the portfolio has been an emphasis on multidisciplinary collaborations, career development of future leaders in clinical trials, understanding the funding landscape, engagement with discovery and translational scientists, and keeping patients at the heart of our research. Moving forward, the priorities of the CTU are to build on this strong foundation with a pipeline of impactful and scientifically rich clinical trials, which will continue to shape the radiotherapy research landscape.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical oncology 医学-肿瘤学

CiteScore

5.20

自引率

8.80%

发文量

332

审稿时长

40 days

期刊介绍： Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.